^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SAR445877

    i
    Associations
    News

    Trials

    Company:
    Sanofi
    Drug class:
    PD1 inhibitor, IL-15R stimulant, IL-2/15Rβγ agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors (NCT05584670)
    Phase 1/2
    Sanofi
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    11/29/2022
    Primary completion :
    01/19/2027
    Completion :
    09/27/2028
    MSI
    |
    HER-2 negative
    |
    Erbitux (cetuximab) • SAR445877